本帖最后由 老马 于 2013-3-13 13:43 编辑
9 V3 X$ H; S. W* r3 K0 U0 {) J4 e1 c4 T5 P" @" n# X2 D% O+ Q' x
健择（吉西他滨）+顺铂+阿瓦斯汀
- X+ s, G% C- I+ k) F: l0 j0 W Gemzar +Cisplatin + Avastin; @1 V5 V, D5 m; n$ z: R
http://annonc.oxfordjournals.org/content/21/9/1804.full8 v0 G$ O* y$ G( z
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
, E4 K* @ i: e# ?1 ZPatients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point. , h0 V0 ^. l7 \9 ?1 P1 K. w) `0 \
Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported. $ ]* V' m7 N$ | F# m! ?; ?
Cisplatin Gemzar Avastin.PDF
(329.84 KB, 下载次数: 226)
: z+ E+ u- b$ r# a5 `. ~* W华为网盘附件：
' f/ [ j3 [' z【华为网盘】ava.JPG
; x0 I4 \8 N) X- [. t% H |
显身卡
